Blog

What changes when evidence moves at the speed of questions.

Deep dives on real-world evidence, RWE strategy, and what we're learning building the evidence infrastructure layer for healthcare.

FeaturedFuture of Evidence

Real-World Evidence in Drug Development: Opportunities and Challenges

A practical guide to where RWE fits across discovery, trial design, study execution, regulatory strategy, launch, market access, and life-cycle management - and what can still go wrong.

Mar 20, 2026/11 min read

RWE Strategy

Approval Isn't Access. Here's Why Payers Need Real-World Evidence.

A treatment can clear regulatory review and still face coverage friction. Real-world evidence helps answer the value, affordability, and effectiveness questions payers and HTA bodies actually decide on.

May 9, 2026/8 min read

AI in Pharma

Why Real-World Evidence Needs More Than a Chatbot

Many pharma teams have tried generic AI for RWE and hit the same wall: fluent outputs without enough trust. Here is how Frekil thinks about what LLMs should and should not do.

May 5, 2026/6 min read

RWE Strategy

When the Control Arm Comes From the Real World

External controls can help rare disease and oncology teams answer questions that a conventional randomized trial cannot always reach. The hard part is proving that the comparison is fair.

Apr 28, 2026/10 min read

Technical

Propensity Scores for Survival Outcomes: What RWE Teams Should Report

A plain-English technical guide to propensity scores for survival RWE, using a post-MI statin example to explain matching, weighting, estimands, survival curves, balance checks, and sensitivity analysis.

Apr 24, 2026/12 min read

Technical

Causal Inference in Real-World Evidence: From DAGs to Target Trials

A practical walkthrough of causal inference for RWE: why naive comparisons fail, how DAGs clarify assumptions, and how target trial emulation turns messy data into a credible study design.

Apr 17, 2026/10 min read

Future of Evidence

RCTs Tell You If a Drug Can Work. RWE Tells You If It Will.

Randomized trials remain essential, but they leave major gaps around real-world effectiveness, patient variation, and value. Real-world evidence is how teams close them.

Apr 6, 2026/9 min read

Future of Evidence

Why RWE Studies Still Take Months: Where the Time Goes

RWE timelines are not driven by the final statistical model. The delay comes from protocol specificity, data access, fit-for-purpose checks, cohort logic, and evidence packaging.

Mar 26, 2026/9 min read

RWE Strategy

FDA's Single-Pivotal-Trial Shift: What It Means for RWE Teams

FDA leaders are signaling that one strong pivotal trial plus confirmatory evidence should become the default approval path. That makes real-world evidence an earlier, more strategic part of development.

Mar 15, 2026/8 min read